The Consumer Justice Foundation Alerts the Public of the Drop in Stock Value of Company Promoting Diet Pill Containing Topiramate Drops Due to Concerns of Birth Defects

Share Article

The Consumer Justice Foundation, a for-profit corporation whose Web site URL can be found at, is staffed by a team of professional consumer advocates whose mission is to provide free informational online resources to the public that relate to the potential dangers of the use of certain medications. The CJF hereby alerts the public of the drop in stock value in a company that has been promoting a new weight-loss drug due to rising concerns regarding the development of birth defects in children whose mothers have used this medication. This medication contains topiramate, which is the active ingredient in Topamax.

The Consumer Justice Foundation, a for-profit corporation staffed by a team of professionals who make it their mission to warn the public regarding the potential dangers of certain medications, hereby alerts the public to a drop in the stock price of a company that is promoting a new weight loss medication that contains topiramate, the active ingredient in Topamax. The stock price fell due to concerns regarding the risk of children of mothers who used this medication developing birth defects.

Specifically, the report appeared in Bloomberg News on December 21, 2011, and it concerned the weight loss drug known as Qnexa. Qnexa is a weight-loss medication that’s manufactured by Vivus, Inc. Qnexa combines topiramate with the appetite suppressant phentermine. The Bloomberg News report stated that the company’s stock, “sank 6.3 percent in late trading after an ingredient in the medicine was shown to be associated with oral clefts in babies whose mothers took it in pregnancy.”

The FDA also asked Vivus, Inc. to perform their analysis of the potential for problems associated with Qnexa within the existing databases that dealt with the prevalence of Topamax birth defects. This analysis, which is named Fortress, found that mothers who had used topiramate during the first trimester of pregnancy had a .29 percent rate of birth defects as compared to .16 percent of birth defects in children born of mothers who had used topiramate before they were pregnant. This analysis is being performed because the FDA has requested it in order to come to a decision regarding whether this medication will be approved for use and sale in the United States.

About the Consumer Justice Foundation

The Consumer Justice Foundation, whose Web site can be found at, is a for-profit organization that serves two purposes for consumers: (1) to provide educational information regarding the policies and procedures of large corporations and how they affect the average consumer; and (2) to provide news updates and resources that continue to update consumers regarding developments taken by corporations that include pharmaceutical drug companies, auto manufacturers and insurance companies so that consumers who have been harmed can use these informational resources to connect to an experienced professional who can help them. The team at the Consumer Justice Foundation is staffed by experienced and passionate consumer advocates whose mission is to raise the awareness of issues that could pose a risk of harm to those who may not otherwise be aware of the dangers they face.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Faith Anderseon
Visit website